Blair William & Co. IL Sells 8,040 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Blair William & Co. IL lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 413,430 shares of the biopharmaceutical company’s stock after selling 8,040 shares during the quarter. Blair William & Co. IL’s holdings in Gilead Sciences were worth $38,189,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Townsquare Capital LLC grew its holdings in shares of Gilead Sciences by 14.4% during the third quarter. Townsquare Capital LLC now owns 134,964 shares of the biopharmaceutical company’s stock worth $11,315,000 after purchasing an additional 16,996 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Gilead Sciences by 118.0% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 249,370 shares of the biopharmaceutical company’s stock worth $20,907,000 after buying an additional 134,993 shares during the last quarter. CreativeOne Wealth LLC raised its position in shares of Gilead Sciences by 41.0% during the 3rd quarter. CreativeOne Wealth LLC now owns 32,135 shares of the biopharmaceutical company’s stock valued at $2,694,000 after buying an additional 9,352 shares in the last quarter. Acuta Capital Partners LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter worth $1,635,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Gilead Sciences by 9.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 848,235 shares of the biopharmaceutical company’s stock worth $71,116,000 after acquiring an additional 74,063 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $12,626,253.06. The trade was a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have issued reports on GILD. Piper Sandler lifted their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. BMO Capital Markets boosted their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research report on Thursday, February 13th. Wells Fargo & Company upped their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $105.12.

Gilead Sciences Trading Up 1.7 %

NASDAQ GILD opened at $111.16 on Friday. The stock’s 50 day moving average is $105.08 and its 200 day moving average is $94.58. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $138.43 billion, a PE ratio of 300.43, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.84%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.